#Switzerland #Zurich #Neurology #NewCelX #DOXA

NewcelX Expands Intellectual Property in China

NewcelX Ltd., a pioneering biotechnology firm, has recently made significant strides in its intellectual property (IP) strategy with the publication of a key patent application in China. This announcement, made on December 11, 2025, marks an essential step in the company's ongoing expansion in the field of neurology and metabolic disorders, emphasizing its commitment to advancing therapeutic innovations.

The DOXA Patent Application

The patent application specifically covers a new class of compounds—quinazoline, benzothiazine, and benzoxazine derivatives—collectively referred to as DOXA. These compounds represent a groundbreaking approach to treating neurological diseases, thereby widening the company's proprietary small-molecule portfolio. NewcelX aims to utilize these advancements to tackle various conditions, ranging from sleep-wake disorders to neurodegenerative diseases such as ALS.

Ronen Twito, CEO and Executive Chairman of NewcelX, highlighted, "The publication of this patent application in China is an important step in expanding the global reach of our IP portfolio. It strengthens the foundation of our DOXA small-molecule platform and supports our long-term strategy to build a diversified therapeutic pipeline in neurology."

Dr. Eric Konofal, the head of the DOXA program, noted the significance of this achievement, stating, "These compounds reflect years of translational work in neuropharmacology and medicinal chemistry, aimed at developing first- or best-in-class treatments for major CNS disorders, from ALS to narcolepsy."

Implications for Neurological and Metabolic Conditions

The DOXA patent covers a broad family of compounds that could have applications in various CNS-related conditions. Notably, narcolepsy and the modulation of orexin signaling are at the forefront of this research. By targeting pathways involved in sleep-wake regulation, neuroinflammation, oxidative stress, and neuronal resilience, DOXA compounds aim to bring breakthroughs not only in neurological conditions but also in associated metabolic disorders.

Recent scientific insights have revealed strong biological connections between sleep regulation and insulin sensitivity. This emerging understanding supports the innovative vision behind the DOXA program. NewcelX is exploring how these mechanisms can integrate with its stem-cell-derived IsletRx program for treating insulin-dependent diabetes, potentially offering a dual approach that leverages metabolic regulation alongside enhanced neurological function.

Future Developments

The successful publication of this patent in China lays the groundwork for future registration in Hong Kong. This move is strategically significant, as it provides an additional layer of protection in a region poised for growth in the biotech sector.

Headquartered in Zurich, Switzerland, NewcelX is committed to developing cutting-edge therapies that address critical health issues in neurology and related fields. Their innovative approach amalgamates advanced stem-cell technologies with extensive neuroscience expertise, positioning them uniquely in a competitive landscape that demands rapid technological advancements.

As the company continues to expand its R&D operations and therapeutic pipeline, the DOXA patent marks not just a milestone for NewcelX but also a beacon of hope for patients suffering from neurological and metabolic diseases worldwide.

In summary, NewcelX is on a promising trajectory with its innovative DOXA compounds, and the recent patent publication heralds a new chapter in the company’s journey towards transformative health solutions. Stakeholders and investors alike will be closely watching as NewcelX moves forward with its ambitious plans and commitment to scientific excellence in the field of biotechnology.